Shares of Amazon.com Inc. (AMZN) are down marginally in pre-market hours following company’s plans to open its first drive-through grocery store in Silicon Valley, according to London’s Sunday Telegraph newspaper. The publication notes that “the launch of a standalone drive-through store would signal a new phase in [Amazon’s] evolving retail ambitions, leveraging its world-class logistics and distribution operation.”
—
Shares of MediciNova Inc. (MNOV) spiked up by more than 26 percent on Monday after the company announced in a press release that the FDA has approved the second phase 2 protocol for MN-001 in NASH which targets NASH patients with hypertriglyceridemia.
Yuichi Iwaki, MD, PhD, President and CEO of MediciNova, Inc., commented, “We are very pleased to have successfully completed the FDA review period and look forward to initiating patient enrollment shortly…”
—
Shares of Bellerophon Therapeutics LLC (BLPH) are lower by 60.13% to $3.05 in early trading on Monday after the company confirmed that top-line results from its PRESERVATION I clinical trial for Bioabsorbable Cardiac Matrix — an implantable medical device being studied for the prevention of heart attacks — showed no statistically significant treatment.
—
BioLineRx, Ltd. (BLRX) shares plunged 31.37% to $1.46 in early trading after its partner, Bellerophon, confirmed negative top-line results from PRESERVATION I clinical trial for Bioabsorbable Cardiac Matrix.
—
Nymox Pharmaceutical Corporation (NYMX) – Shares halted in early trading following the company’s announcement that its U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate for BPH have successfully met the pre-specified primary endpoint.
Leave a Reply